Qiao Li, Zhang Yuetong, Huang Pin
State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China.
Department of Rehabilitation Medicine, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Cancer Rep (Hoboken). 2025 Sep;8(9):e70325. doi: 10.1002/cnr2.70325.
YRDC has emerged as a potential biomarker in cancer, yet its prognostic value, oncogenic mechanisms, role in immune infiltration, and anticancer drugs efficacy in pan-cancer remained poorly understood.
This study aimed to comprehensively investigate YRDC's role in pan-cancer and to explore the potential effects of YRDC on the immune infiltration pattern and anticancer drug sensitivity.
Based on bioinformatics analysis of multi-omics data, we firstly demonstrated that YRDC was markedly overexpressed and associated with worse prognosis in various tumors. Further, our results indicated that genetic alterations, copy number variations, and methylation levels of YRDC might explain the different YRDC expression between tumors and controls. Additionally, YRDC might promote cancer via enhancing tumor cell proliferation, modulating immune cell infiltration, and enhancing drug resistance. Notably, YRDC emerged as a potential biomarker for predicting immunotherapy response and targeted drug efficacy.
Our study identifies YRDC as a novel therapeutic target and a promising biomarker for cancer progression, immunotherapy response, and targeted drug sensitivity across pan-cancers. These findings provide evidence for further research into YRDC's role in cancer biology and future clinical exercises.
YRDC已成为癌症中一种潜在的生物标志物，但其预后价值、致癌机制、在免疫浸润中的作用以及在泛癌中的抗癌药物疗效仍知之甚少。
本研究旨在全面探究YRDC在泛癌中的作用，并探讨YRDC对免疫浸润模式和抗癌药物敏感性的潜在影响。
基于多组学数据的生物信息学分析，我们首先证明YRDC在各种肿瘤中显著过表达且与较差的预后相关。此外，我们的结果表明，YRDC的基因改变、拷贝数变异和甲基化水平可能解释肿瘤与对照之间YRDC表达的差异。此外，YRDC可能通过增强肿瘤细胞增殖、调节免疫细胞浸润和增强耐药性来促进癌症。值得注意的是，YRDC成为预测免疫治疗反应和靶向药物疗效的潜在生物标志物。
我们的研究将YRDC确定为一种新型治疗靶点以及泛癌中癌症进展、免疫治疗反应和靶向药物敏感性的有前景的生物标志物。这些发现为进一步研究YRDC在癌症生物学中的作用和未来临床应用提供了证据。
